TreeFrog Therapeutics Names James Sterling as Chief Financial Officer

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer to Support Next Phase of Growth

TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies through its proprietary C-Stem™ technology, has appointed James Sterling as its new Chief Financial Officer (CFO), effective November 1, 2026. The appointment strengthens the company’s executive leadership team as it prepares for its next phase of growth and continues advancing its work in regenerative medicine and cell therapy manufacturing.

In his new role, Sterling will oversee TreeFrog Therapeutics’ finance, investor relations and corporate development activities. He will report directly to Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics, and will contribute to the company’s financial strategy, business planning and corporate development priorities.

Sterling joins TreeFrog with extensive experience in corporate finance, capital markets, strategic planning and financial leadership across the biotechnology, therapeutics and diagnostics sectors. His background includes serving as CFO of Bluebird Bio, now known as Genetix Biotherapeutics, and Renalytix plc, where he supported financial operations, corporate strategy, clinical development and commercial activities.

The appointment comes as TreeFrog Therapeutics continues working to address manufacturing challenges associated with cell therapies. The company is developing technologies intended to support the scalable production of cell-based treatments, an important requirement for expanding the availability and commercial potential of regenerative medicines.

Through its proprietary C-Stem™ platform and broader industry partnerships, TreeFrog aims to contribute to the development and manufacturing of next-generation cell therapies. Sterling’s experience in biotechnology finance and capital markets is expected to support the company’s efforts as it advances its technology, develops strategic relationships and pursues future growth opportunities.

Leadership Appointment Supports TreeFrog’s Growth Strategy

The appointment of a new CFO represents an important addition to TreeFrog Therapeutics’ executive leadership as the company continues building its position in the regenerative medicine sector.

As CFO, Sterling will be responsible for overseeing the company’s financial management and supporting its broader business strategy. His responsibilities will include finance, investor relations and corporate development, placing him at the center of the company’s financial planning and external stakeholder engagement.

These functions are particularly important for biotechnology companies operating in the cell therapy field, where research, technology development, manufacturing infrastructure and clinical advancement can require significant investment over extended periods.

Financial leadership also plays a central role in determining how companies allocate resources, manage operational priorities and establish relationships with investors and strategic partners. For a company developing enabling technologies for regenerative medicine, these activities can influence its ability to advance research programs, expand manufacturing capabilities and pursue commercial opportunities.

Sterling’s experience across both biotechnology companies and financial markets provides a combination of operational and capital markets knowledge that may support TreeFrog as it moves into its next stage of development.

Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics, welcomed Sterling to the company and highlighted the value of his experience across biotechnology finance and Wall Street.

Rothera said Sterling brings a valuable combination of biotech CFO and Wall Street experience that supports the company’s ambition to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field.

The CEO’s comments reflect the company’s intention to strengthen its financial and strategic capabilities while continuing to develop its technology platform and business relationships across the cell therapy industry.

Extensive Experience Across Biotechnology and Diagnostics

Sterling brings a broad background in corporate finance and executive leadership, with experience spanning gene therapy, kidney disease diagnostics, digital pathology and pharmacovigilance.

Most recently, he served as Chief Financial Officer of Bluebird Bio, which is now known as Genetix Biotherapeutics. Bluebird Bio is a gene therapy company that has developed three FDA-approved commercial therapies for genetic disorders.

During his time at the company, Sterling gained experience in the financial and strategic requirements of a biotechnology business operating in the commercial gene therapy market. Gene therapy development and commercialization involve complex considerations, including research investment, regulatory requirements, manufacturing operations, market access and long-term commercial planning.

His experience at Bluebird Bio provides exposure to the financial challenges and opportunities associated with bringing advanced therapies from development into commercial use.

The company has developed three FDA-approved therapies for genetic disorders, placing it within a specialized segment of the biotechnology industry focused on treatments designed to address underlying genetic conditions.

Sterling’s work in this environment adds to his understanding of the financial management requirements of companies developing advanced therapeutic products. This experience may be relevant to TreeFrog as it continues pursuing opportunities in regenerative medicine and cell therapy development.

Previous CFO Role at Renalytix

Before joining Bluebird Bio, Sterling served as Chief Financial Officer of Renalytix plc, a diagnostics company focused on kidney disease.

At Renalytix, he helped guide the business through clinical development and commercial launch. His responsibilities also included leading the company’s initial public offerings in the United Kingdom and on the Nasdaq stock market.

This experience provided Sterling with exposure to several important stages in the development of a healthcare technology company. These included supporting clinical progress, preparing for commercial operations, managing financial strategy and accessing public capital markets.

Renalytix operates in the diagnostics sector, where companies must navigate the development and validation of diagnostic technologies while establishing commercial pathways and relationships with healthcare stakeholders.

Leading initial public offerings in both the UK and the United States also gave Sterling experience in capital raising and investor engagement across different financial markets. These activities require financial planning, regulatory coordination, corporate governance and communication with institutional and public-market investors.

His experience at Renalytix is particularly relevant to his new responsibilities at TreeFrog, which include investor relations and corporate development in addition to financial oversight.

For biotechnology companies, the ability to communicate development progress, business strategy and financial priorities to investors can be important in maintaining stakeholder confidence and supporting long-term growth plans.

Sterling’s background in public-market transactions and financial advisory may therefore contribute to TreeFrog’s efforts to develop its business and strengthen its relationships with investors and industry partners.

Experience in Digital Pathology and Pharmacovigilance

In addition to his permanent CFO positions, Sterling has held interim CFO roles at companies operating in digital pathology and pharmacovigilance.

These areas represent different but important parts of the healthcare and life sciences industry.

Digital pathology involves the use of digital technologies to capture, manage and analyze pathology information. It can support the evaluation of tissue samples and the use of computational tools in diagnostic workflows.

Pharmacovigilance focuses on monitoring and evaluating the safety of medicines, including the identification, assessment and reporting of adverse drug reactions and other safety-related information.

Sterling’s work with companies in these sectors adds further breadth to his experience across healthcare technology and life sciences business models. It also reflects his involvement in organizations operating at different stages of development and across a range of specialized healthcare markets.

For TreeFrog Therapeutics, this combination of experience may provide useful perspectives as it continues developing its position within the regenerative medicine ecosystem.

Earlier Career in Investment Banking and Strategic Consulting

Before moving into senior financial leadership positions within the biotechnology and diagnostics industries, Sterling held leadership roles in investment banking and financial advisory.

These positions provided experience in corporate finance, financial transactions and strategic decision-making. Investment banking and financial advisory work often involves supporting companies with capital raising, financial structuring, mergers and acquisitions, valuation and other strategic business activities.

Sterling also worked as a management consultant within the corporate strategy division of Booz Allen Hamilton, now known as Strategy& and part of PwC.

His consulting experience involved corporate strategy and business planning, adding another dimension to his background in financial leadership.

The combination of investment banking, management consulting and CFO experience gives Sterling exposure to both the financial and operational aspects of business development. It also provides experience in evaluating strategic opportunities, managing financial priorities and supporting organizational growth.

These capabilities are relevant to TreeFrog as it seeks to develop partnerships, advance its technology and strengthen its role in the regenerative medicine market.

Board Experience and Academic Background

Alongside his executive experience, Sterling serves on the board of Star Mountain Lower Middle-Market Capital Corp., where he chairs the audit committee.

The audit committee role provides additional exposure to corporate governance, financial oversight and risk management. These responsibilities are important for organizations seeking to maintain strong financial controls, transparent reporting and effective board-level supervision.

His board experience complements his background as a CFO and financial executive, providing insight into governance and accountability from both management and director perspectives.

Sterling holds a Master of Business Administration (MBA) from Columbia Business School and a Bachelor of Arts (B.A.) degree from Boston University.

His academic qualifications, together with his professional experience, provide a foundation in business strategy, financial management and corporate leadership.

TreeFrog Therapeutics Focuses on Scalable Cell Therapy Manufacturing

TreeFrog Therapeutics is developing cell therapies and manufacturing technologies intended to address some of the challenges associated with scaling cell-based treatments.

Cell therapies are an important area of regenerative medicine, with potential applications across a range of diseases and medical conditions. These treatments use living cells as therapeutic agents and may involve complex production processes that differ from conventional pharmaceutical manufacturing.

Despite advances in research and clinical development, manufacturing remains a significant challenge for the broader cell therapy sector. Producing consistent, high-quality cells at the scale required for clinical development and commercial supply can be technically demanding.

Cell therapy manufacturing processes must address several requirements, including cell quality, reproducibility, scalability and consistency between production batches. These considerations are important because manufacturing performance can influence the development, availability and commercial viability of cell-based treatments.

TreeFrog Therapeutics is working to address these challenges through its proprietary C-Stem™ technology.

The company’s technology platform is intended to support the scalable production of cell therapies, with the broader objective of enabling wider adoption of regenerative medicine. By focusing on manufacturing capabilities, TreeFrog aims to contribute to the infrastructure required for the development and potential commercialization of advanced cell-based treatments.

The company is also pursuing opportunities to work with industry partners and develop its own proprietary therapies. This approach positions TreeFrog across both the technology-enabling and therapeutic development aspects of regenerative medicine.

C-Stem™ Technology and Industry Partnerships

TreeFrog’s C-Stem™ technology is central to its strategy of developing scalable cell therapy solutions.

The company aims to use the platform to help overcome manufacturing limitations that can restrict the wider development and adoption of regenerative medicines. Scalable production is particularly important as cell therapy programs progress through clinical development and potentially move toward commercial supply.

Industry partnerships can also play an important role in advancing cell therapy technologies. Collaboration between technology developers, biotechnology companies and other healthcare organizations can support the development of manufacturing processes and help address technical and operational requirements.

TreeFrog’s strategy includes working with industry partners while also developing its own proprietary therapies. The combination allows the company to pursue opportunities as a technology provider and as a developer of regenerative medicine products.

Sterling’s appointment comes as the company continues building the financial and corporate capabilities needed to support these ambitions.

New CFO Highlights Cell Therapy Manufacturing Opportunity

Commenting on his appointment, James Sterling said he was pleased to join TreeFrog Therapeutics at an important point in the company’s development.

He highlighted the manufacturing challenges facing the cell therapy industry and said that addressing these issues could help enable broader adoption of regenerative medicines.

Sterling also emphasized the potential of TreeFrog’s proprietary technologies and its approach to working through industry partnerships and developing its own therapies.

His comments reflect the opportunity to strengthen the manufacturing foundations needed to support the wider regenerative medicine sector. As cell therapies continue to advance, companies developing scalable production technologies may play an important role in helping translate scientific progress into accessible treatments.

Sterling’s new responsibilities across finance, investor relations and corporate development will place him in a position to support TreeFrog’s financial strategy and business development activities as the company pursues these opportunities.

Strengthening Financial Leadership for the Next Phase

The appointment of James Sterling as CFO marks a new leadership addition for TreeFrog Therapeutics as it continues developing its C-Stem™ platform and expanding its activities in regenerative medicine.

His background includes senior financial roles at Bluebird Bio and Renalytix, experience with initial public offerings in the UK and on Nasdaq, interim CFO positions in digital pathology and pharmacovigilance, and earlier work in investment banking and corporate strategy consulting.

This combination of experience across therapeutics, diagnostics and financial markets is expected to support TreeFrog’s financial management, investor engagement and corporate development priorities.

Effective November 1, 2026, Sterling will report to CEO Mark Rothera and join the company’s executive leadership team. His appointment comes as TreeFrog continues working to address cell therapy manufacturing challenges through its proprietary technology, industry partnerships and therapeutic development activities.

As the regenerative medicine sector advances, scalable manufacturing remains an important consideration for companies seeking to bring cell-based treatments to more patients. TreeFrog Therapeutics is positioning its technology and business strategy around this opportunity, while Sterling’s appointment adds financial and strategic leadership to support the company’s next stage of growth.

About TreeFrog Therapeutics

TreeFrog Therapeutics is a regenerative medicine biotech set to unlock access to cell therapies for millions of patients with a lead program in Parkinson’s disease. TreeFrog is unique in its approach to cell therapy development, bringing together biophysicists, cell biologists, and bioproduction engineers to address the challenges of the industry – producing and differentiating cells of quality at unprecedented scale, cost-effectively.

To succeed in its mission, TreeFrog operates a business model that includes its own therapeutic programs and strategic partnerships with leading biopharma players to support their cell therapy initiatives. Since 2021, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine. TreeFrog is based in Bordeaux, France and Cambridge, Massachusetts, USA.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter